Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
1. A method for preventing, reducing, or eliminating cardiotoxicity induced by an anthracycline or salt thereof in a subject, the method comprising administering to the subject an effective amount of a protective agent prior to or simultaneously with the anthracycline or salt thereof, wherein the administration of the protective agent provides an effective amount of myricetin in the subject, thereby preventing, reducing, or eliminating the cardiotoxicity induced by the anthracycline or salt thereof in the subject.
2. The method of claim 1 , wherein the protective agent is myricetin or derivative thereof.
3. The method of claim 1 , wherein the protective agent is administered intravenously.
4. The method of claim 1 , wherein the subject suffers from cancer.
5. The method of claim 1 , further comprising administering an effective amount of a second protective agent prior to or simultaneously with the anthracycline or salt thereof.
6. The method of claim 5 , wherein the second protective agent is dexrazoxane or derivative thereof.
7. The method of claim 1 , wherein the anthracycline is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.
8. The method of claim 1 , wherein the protective agent is administered to the subject at least about 5 minutes before the administration of the anthracycline or salt thereof.
9. The method of claim 1 , wherein the protective agent and the anthracycline or salt thereof are administered simultaneously.
10. The method of claim 9 , wherein the protective agent and the anthracycline or salt thereof are co-formulated in a liquid composition.
11. The method of claim 1 , wherein the cardiotoxicity comprises one or more of cardiac tissue damage, electrophysiological dysfunction, contractile dysfunction, mitochondrial toxicity, DNA double strand break in cardiomyocytes, apoptosis, and oxidative stress.
12. The method of claim 11 , wherein the electrophysiological dysfunction comprises QT prolongation or QTc prolongation, and/or wherein the contractile dysfunction comprises reduced ejection fraction (EF) or reduced fractional shortening (FS).
13. The method of claim 1 , wherein the subject has a decreased QTc interval after administering the protective agent.
14. A method of treating cancer in a subject without inducing cardiotoxicity or with reduced cardiotoxicity, comprising administering to the subject an effective amount of an anthracycline or salt thereof, wherein the subject has an effective amount of myricetin, thereby preventing, reducing, or eliminating the cardiotoxicity induced by the anthracycline or salt thereof in the subject.
15. The method of claim 14 , wherein the method further comprises administering to the subject an effective amount of myricetin or derivative thereof prior to the administration of the anthracycline or salt thereof.
16. The method of claim 15 , wherein the effective amount of myricetin or derivative thereof is administered to the subject at least about 5 minutes prior to the administration of the anthracycline or salt thereof.
17. The method of claim 14 , wherein the anthracycline is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.
18. The method of claim 14 , wherein the cardiotoxicity comprises one or more of cardiac tissue damage, electrophysiological dysfunction, contractile dysfunction, mitochondrial toxicity, DNA double strand break in cardiomyocytes, apoptosis, and oxidative stress.
19. The method of claim 18 , wherein the electrophysiological dysfunction comprises QT prolongation or QTc prolongation, and/or wherein the contractile dysfunction comprises reduced ejection fraction (EF) or reduced fractional shortening (FS).